In May 2023, Incognito Blog reported the approval of human experimentation in the neurotechnology company, Neuralink, by the Food and Drug Administration (FDA). These experiments aim to help people suffering from loss of motor and sensory abilities in the cervical area of the spinal cord, and recruitment has begun.
According to Neuralink, the PRIME (Precise Robotically Implanted Brain Computer Interface) clinical trial will be conducted using robots to surgically implant chips in the area of the brain that controls movement intentions. The company’s primary goal is to give people the ability to control computer cursors or keyboards using only their thoughts.
The patient registry portal is available now and people with spinal cord injuries or amyotrophic lateral sclerosis (ALS) have been advised to sign up and assess their eligibility for current and future experiments.
